A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients.


Kremers, H M; Funch, D P; Robson, R A; Nalesnik, M A; Ebrahim, S; Cecka, M J; Opelz, G; Dreyer, N A; Walker, A M; (1999) A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients. Pharmacoepidemiology and drug safety, 8 (7). pp. 509-18. ISSN 1053-8569

Full text not available from this repository.

Abstract

Renal transplant recipients who are chronically immunosuppressed by drugs are at a higher risk of developing malignancies. Commonly observed malignancies are several forms of posttransplant lymphoproliferative disorders (PTLD), skin, lip and gynaecological cancers. The risk is associated with many risk factors including the extent of immunosuppression. Mycophenolate mofetil (MMF) is an immunosuppressant, indicated for the prophylaxis of organ rejection in patients receiving allogenic renal and heart transplants. During the European approval of MMF for renal transplantation, the question was raised as to whether the use of MMF was associated with an increased risk of PTLD in comparison with alternate immunosuppressive regimens. In response, F. Hoffman-La Roche Ltd set up a prospective observational cohort study with a companion case-control study. This paper describes the objectives and the methods of these studies along with the rationale of the methodology.

Item Type: Article
PubMed ID: 15073894
URI: http://researchonline.lshtm.ac.uk/id/eprint/20367

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
267Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item